Medical University of South Carolina

• LiveKidney has enrolled the first patient in a Phase I/IIa clinical trial evaluating LK-SC001, a subcutaneous UC-MSC therapy, for lupus nephritis and systemic lupus erythematosus at the Medical University of South Carolina. • The investigational therapy utilizes umbilical cord-derived mesenchymal stromal cells in a proprietary hydrogel formulation designed to release immunomodulatory compounds that may improve kidney function and reduce inflammation. • Current lupus treatments are effective in only 40% of patients, highlighting the significant unmet need that LK-SC001 aims to address through its novel mechanism targeting the complex immunological nature of the disease.

A study by the Medical University of South Carolina demonstrates that home administration of long-acting injectable antiretroviral therapy (ART) for HIV patients is as safe and effective as clinic-based administration.

A novel patient navigation intervention (NDURE) doubled the rate of timely post-operative radiation therapy initiation in head and neck cancer patients, showing a 35% improvement over usual care.

A landmark 25-year study reveals regular dental flossing is linked to a 22% lower risk of ischemic stroke and 44% reduction in cardioembolic stroke risk, independent of other oral hygiene practices.

The Medical University of South Carolina (MUSC) has been selected as one of seven national sites to test an innovative fully implantable cochlear implant system without external components.

Research from the Medical University of South Carolina indicates that single-dose IVIG therapy (2g/kg) may be sufficient for clearing BK viral load in nephropathy patients, potentially reducing overall treatment costs.

Healthcare experts at the 2024 World Conference on Lung Cancer presented innovative approaches to improve lung cancer screening uptake, emphasizing the need for tailored recruitment strategies and digital solutions.